Compare Cytokinetics Inc (CYTK) vs GFL Environmental Inc. Subordinate voting shares no par value (GFL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cytokinetics Inc vs GFL Environmental Inc. Subordinate voting shares no par value — how do they compare? Cytokinetics Inc trades at $62.64 (market cap $8.62B), while GFL Environmental Inc. Subordinate voting shares no par value trades at $42.56 (market cap $18.46B). The key difference: GFL Environmental Inc. Subordinate voting shares no par value is far larger — about 2.1× Cytokinetics Inc's market cap, and GFL Environmental Inc. Subordinate voting shares no par value pays a 0.16% dividend while Cytokinetics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Cytokinetics Inc for 19 Days and GFL Environmental Inc. Subordinate voting shares no par value for 0 Days on average.
| CYTK | GFL | |
|---|---|---|
Market Cap | $8.62B | $18.46B |
Volume | 2,594,626 | 2,438,353 |
Sector | Health | Industrials |
52-Week High | $87.26 | $46.51 |
52-Week Low | $54.76 | $33.54 |
Typical Hold Time | 19 Days | 0 Days |
Enterprise Value | $8.72B | $25.43B |
Dividend Yield | — | 0.16% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Cytokinetics (CYTK) trades at $62.48, up 2.23% today, but faces bearish technical signals with 18 sell indicators versus 4 buy signals. The company shows strong revenue growth potential with recent positive Phase 3 trial results for aficamten in non-obstructive HCM, though it operates at significant losses with a -1,321% net income margin. Cash flow remains heavily dependent on financing activities, with operating cash flow negative at -$555 million in 2026.
Wall Street maintains strong bullish sentiment with 97% buy ratings and a $112.60 consensus price target, representing 80% upside potential. Key risks include continued cash burn, competitive pressure from Bristol Myers Squibb's Camzyos, and the need for successful commercialization of pipeline drugs. The stock's valuation appears stretched at 114x sales given current financial performance.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Cytokinetics Inc
Cytokinetics is a biopharmaceutical company focused on muscle biology. It develops muscle activators and inhibitors as potential treatments for debilitating diseases where muscle performance is compromised or declining.
Read more on CYTK →About GFL Environmental Inc. Subordinate voting shares no par value
GFL Environmental provides environmental services across Canada and the United States. Its operations include solid waste management and other waste and environmental solutions.
Read more on GFL →
